Related references
Note: Only part of the references are listed.Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
Chungyee Leung-Hagesteijn et al.
CANCER CELL (2013)
Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins
James A. Nathan et al.
CELL (2013)
Immunoproteasomes Are Important for Proteostasis in Immune Responses
Frederic Ebstein et al.
CELL (2013)
Proteasome inhibitors in acute leukemia
Denise Niewerth et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors
Denise Niewerth et al.
HAEMATOLOGICA (2013)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
Eva M. Huber et al.
CELL (2012)
Emerging roles of immunoproteasomes beyond MHC class I antigen processing
Frederic Ebstein et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Immunoproteasomes at the interface of innate and adaptive immune responses: two faces of one enzyme
Elke Krueger et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance
Andrew J. Kale et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells
N. E. Franke et al.
LEUKEMIA (2012)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
Discovery and Development of Second-Generation Proteasome Inhibitors
Christopher J. Kirk
SEMINARS IN HEMATOLOGY (2012)
The Immunoproteasome as a Target in Hematologic Malignancies
Deborah J. Kuhn et al.
SEMINARS IN HEMATOLOGY (2012)
Bacterial Self-Resistance to the Natural Proteasome Inhibitor Salinosporamide A
Andrew J. Kale et al.
ACS CHEMICAL BIOLOGY (2011)
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
Ajita V. Singh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells
Erika Suzuki et al.
PLOS ONE (2011)
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
Jacob P. Laubach et al.
EXPERT REVIEW OF HEMATOLOGY (2011)
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit
Christopher Blackburn et al.
BIOCHEMICAL JOURNAL (2010)
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia
Aldo M. Roccaro et al.
BLOOD (2010)
Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress
Ulrike Seifert et al.
CELL (2010)
Bortezomib Retreatment in Relapsed Multiple Myeloma - Results from a Retrospective Multicentre Survey in Germany and Switzerland
I. Hrusovsky et al.
ONCOLOGY (2010)
Proteasomes in immune cells: more than peptide producers?
Marcus Groettrup et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
Molecular mechanisms of proteasome assembly
Shigeo Murata et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits
Antonia Busse et al.
CANCER (2008)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
IFN-γ-induced immune adaptation of the proteasome system is an accelerated and transient response
S Heink et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)